The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system. In an effort to modernize and provide transparency on ...

A new commission will investigate the prevalence of SSRI antidepressants as adverse event reports document hundreds of cases of homicidal ideation and homicide. A newly released analysis of FDA ...

Please provide your email address to receive an email when new articles are posted on . The FDA Adverse Event Reporting System will now host daily publications, instead of quarterly. The agency’s goal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and reshape the U.S' healthcare infrastructure, the U.S. drug regulator has unveiled ...

The U.S. Food and Drug Administration said that it has begun the daily publication of adverse event reports related to drugs and biological products. This marks a shift from the previous quarterly ...

To increase transparency, the agency is publishing data from the FDA Adverse Event Reporting System daily rather than quarterly. (HealthDay News) — The U.S. Food and Drug Administration is now ...

Last month, the US Food and Drug Administration (FDA) announced that it would begin daily publication of adverse event data for drugs and biologics via the FDA Adverse Event Reporting System (FAERS).

The Food and Drug Administration is seeking to develop a database of de-identified electronic medical records to help the agency better track adverse drug effects. Currently, adverse drug event ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...